Brief: Theriva Biologics Reports 2022 Loss Per Share Of $1.31
30/03/2023 14:33
March 30 (Reuters) - Theriva Biologics Inc TOVX.A :
* THERIVA BIOLOGICS REPORTS FOURTH QUARTER AND FULL-YEAR
2022
OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS
* THERIVA BIOLOGICS INC - FY LOSS PER SHARE $1.31
* THERIVA BIOLOGICS INC - AS OF DECEMBER 31, 2022, THERIVA
BIOLOGICS REPORTS $41.8 MILLION IN CASH, WHICH IS EXPECTED TO
PROVIDE RUNWAY INTO Q3 OF 2024
Source text for Eikon: ID:nGNX1pdrZf
Further company coverage: TOVX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theriva Biologics
See all newsTheriva Biologics Q2 net loss narrows on lower R&D costs, expenses
Brief: Theriva™ Biologics Announces Upcoming Presentation Of Additional Data From The Virage Phase 2B Clinical Trial Of Vcn-01 In Metastatic Pancreatic Cancer At Aacr 2026 Annual Meeting
Brief: Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications
Brief: Theriva Biologics Implements 32% Workforce Reduction - SEC Filing
Brief: Theriva™ Biologics Announces Presentation Of Data From Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025